As a leading biopharma company in Canada, Bristol Myers Squibb (BMS) is committed to scientific excellence and continued investment in R&D. BMS combines the agility of a biotech with the reach and resources of an established pharmaceutical company.
In oncology, hematology, immunology and cardiovascular disease – and with one of the most diverse and promising pipelines in the industry – we focus on innovations that drive meaningful change.
BMS established roots in Canada in 1925 and has become a recognized pharmaceutical company with breakthroughs that advanced the treatment of serious diseases affecting Canadians. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and Hepatitis C.
Across Canada and the world, we are making improvements in disease states and we are finding new ways to treat challenging diseases that will significantly impact patients.
Canada is a world-leading destination to conduct early development studies including first-in-human trials. In 2020, BMS had the second highest number of active clinical trials amongst the top 20 pharmaceutical companies in Canada.
We are united in our relentless quest to deliver revolutionary patient care solutions so Canadians can live healthier and longer lives.